We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+31.84%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
+$3.55M
Cap. Flow
-$50.9M
Cap. Flow %
-13.55%
Top 10 Hldgs %
91.86%
Holding
26
New
1
Increased
9
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.1M
2
RLYB icon
Rallybio
RLYB
+$3.92M
3
IMA
ImageneBio Inc
IMA
+$1.13M
4
KZR
Kezar Life Sciences
KZR
+$939K
5
CGEM icon
Cullinan Oncology
CGEM
+$903K

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$44M
2
AKUS
Akouos Inc
AKUS
+$8.71M
3
PLRX icon
Pliant Therapeutics
PLRX
+$5.01M
4
RPTX
Repare Therapeutics
RPTX
+$4.03M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Miscellaneous 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$102M 27.06%
923,800
-677,985
-42% -$44M
PLRX icon
2
Pliant Therapeutics
PLRX
$71.2M
$61.3M 16.32%
3,169,892
-239,866
-7% -$5.01M
VECT
3
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$47.6M 12.68%
5,492,893
+1,373,321
+33% +$11.1M
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$41.2M 10.97%
2,800,126
-269,721
-9% -$4.03M
CGEM icon
5
Cullinan Oncology
CGEM
$1.45B
$35M 9.32%
3,317,544
+74,359
+2% +$903K
LRMR icon
6
Larimar Therapeutics
LRMR
$421M
$14.3M 3.82%
3,473,366
+58,218
+2% +$199K
CMPX icon
7
Compass Therapeutics
CMPX
$454M
$14.2M 3.79%
2,829,712
– –
KZR
8
DELISTED
Kezar Life Sciences
KZR
$13.3M 3.54%
188,945
+12,666
+7% +$939K
KROS icon
9
Keros Therapeutics
KROS
$223M
$10.3M 2.75%
215,059
+14,830
+7% +$693K
OMGA
10
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$6.03M 1.61%
1,055,882
– –
RLYB icon
11
Rallybio
RLYB
$89M
$4.77M 1.27%
90,764
+66,477
+274% +$3.92M
IMA
12
ImageneBio Inc
IMA
$60.5M
$4.36M 1.16%
136,448
+35,256
+35% +$1.13M
DTIL icon
13
Precision BioSciences
DTIL
$232M
$4.22M 1.13%
118,327
-4,167
-3% -$165K
TSVT
14
DELISTED
2seventy bio
TSVT
$3.12M 0.83%
333,252
-196,971
-37% -$2.78M
ORTX
15
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.96M 0.79%
798,740
– –
INZY
16
DELISTED
Inozyme Pharma
INZY
$2.32M 0.62%
2,204,876
+208,599
+10% +$365K
FRLN
17
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$2.29M 0.61%
320,961
– –
CRVS icon
18
Corvus Pharmaceuticals
CRVS
$1.24B
$2.03M 0.54%
2,384,402
– –
GTHX
19
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.81M 0.48%
333,945
+10,000
+3% +$83.8K
OVID icon
20
Ovid Therapeutics
OVID
$572M
$1.61M 0.43%
864,822
– –
ONCR
21
DELISTED
Oncorus, Inc.
ONCR
$600K 0.16%
2,367,436
– –
LABD icon
22
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.2M
$431K 0.11%
2,500
-2,500
-50% -$512K
PLRX icon
23
CALL
Pliant Therapeutics
PLRX
$71.2M
$29.3K 0.01%
+30,000
New +$627K
NKTX icon
24
Nkarta
NKTX
$197M
– –
-117,599
Closed -$1.55M
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-15,170
Closed -$3.43M
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, CHI Advisors held 26 positions worth $375M, up 0.96% from $372M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

CHI Advisors withdrew a net $50.9M in Q4 2022, closing 3 positions and reducing 6 holdings. Its most notable exit was Akouos Inc, an estimated $8.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, CHI Advisors added an estimated $11.1M to VectivBio Holding AG Ordinary Shares.

  • CHI Advisors added most to VectivBio Holding AG Ordinary Shares in Q4 2022, an estimated $11.1M increase.
  • CHI Advisors's biggest Q4 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $44M.
  • CHI Advisors fully exited Akouos Inc in Q4 2022, selling an estimated $8.71M.
  • CHI Advisors's ten largest holdings make up 92% of its $375M portfolio in Q4 2022.
  • CHI Advisors opened 1 new position and closed 3 in Q4 2022.
  • CHI Advisors's portfolio value rose 0.96% quarter-over-quarter to $375M.

Based on CHI Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.